Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Onartuzumab in Solid Tumors
NCT02488330Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of onartuzumab in solid tumor, sponsored by Roche. Started Aug 2015; status: completed.
02
Drugs
onartuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02488330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488330.